All In Biotech

Drug Trial Radar · NCT01702571

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment

Last checked: Nov 20, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,185

Actual

Start

Nov 27, 2012

Primary completion

Jul 31, 2020

Study completion Jul 31, 2020

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 8, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.

Conditions

  • Breast Cancer

Interventions

  • Trastuzumab EmtansineDrug

    Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events of Primary Interest (AEPIs)Time frame: Baseline up to approximately 7 years

Locations

300 sites in 43 countries. Site status is shown where the registry gives one.

  • CEMIC

    Buenos Aires, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • Hospital Privado De Comunidad; General Practice

    Mar del Plata, Argentina

  • Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research

    North Sydney, New South Wales, Australia

  • Calvary Mater Newcastle; Medical Oncology

    Waratah, New South Wales, Australia

  • Westmead Hospital; Medical Oncology and Pallative Care

    Westmead, New South Wales, Australia

  • Haematology & Oncology Clinics of Australia Research Centre

    South Brisbane, Queensland, Australia

  • Ashford Cancer Center Research

    Kurralta Park, South Australia, Australia

  • Peter MacCallum Cancer Centre; Medical Oncology

    Melbourne, Victoria, Australia

  • Sunshine Hospital; Oncology Research

    St Albans, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.

    Salzburg, Austria

  • Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie

    Vienna, Austria

  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie

    Vienna, Austria

  • Institut Jules Bordet

    Anderlecht, Belgium

  • UZ Brussel

    Brussels, Belgium

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • GHdC Site Notre Dame

    Charleroi, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • CHU Sart-Tilman

    Liège, Belgium

  • Clinique Ste-Elisabeth

    Namur, Belgium

  • Sint Augustinus Wilrijk, Apotheek

    Wilrijk, Belgium

  • *X*Instituto Nacional do Cancer - INCA

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Pesquisas Oncologicas - CEPON

    Florianópolis, Santa Catarina, Brazil

  • Hospital Sirio Libanes; Centro de Oncologia

    São Paulo, São Paulo, Brazil

  • Hospital Sao Jose

    São Paulo, São Paulo, Brazil

  • MHAT Serdika; Department of medical oncology

    Sofia, Bulgaria

  • SHATO - Sofia

    Sofia, Bulgaria

  • SHATOD - Sofia

    Sofia, Bulgaria

  • District Oncology Dispensary Wit Stationary

    Varna, Bulgaria

  • BC Cancer - Surrey

    Surrey, British Columbia, Canada

  • British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Dr. H. Bliss Murphy Cancer Centre; Oncology

    St. John's, Newfoundland and Labrador, Canada

  • Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials

    Barrie, Ontario, Canada

  • London Regional Cancer Centre

    London, Ontario, Canada

  • Southlake Regional Health Center; Community Care Clinic / Oncology

    Newmarket, Ontario, Canada

  • St. Michael'S Hospital

    Toronto, Ontario, Canada

Showing 40 of 300 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.